GO TO CMA Home
GO TO Inside CMA
GO TO Advocacy and Communications
GO TO Member Services
GO TO Publications
GO TO Professional Development
GO TO Clinical Resources

GO TO What's New
GO TO Contact CMA
GO TO Web Site Search
GO TO Web Site Map


CMAJ
CMAJ - May 30, 2000JAMC - le 30 mai 2000

Research Update
Turning T cells to the task of fighting cancer

CMAJ 2000;162:1604


In addition to their essential role in fighting infection, T lymphocytes are proving their use in eliminating cancer cells. This ability is at the heart of recent research into immunotherapy for cancer. Now researchers at the Memorial Sloan-Kettering Cancer Center in New York have developed stable, artificial cells that stimulate T cells to fight cancer (Nat Biotechnol 2000;18:405-9).

"There are cells in the body that are specialized in the function of presenting antigens to T cells," says lead researcher Dr. Michel Sadelain. "These cells, termed 'antigen-presenting cells,' naturally express a cohort of molecules that render them effective in this task. However, the generation of such cells for the purpose of inducing specific T cells is labour-intensive and time-consuming. We therefore examined what are the minimal components needed to make genetically engineered cells that are potent activators of T cells that are able to recognize and destroy tumour cells."

Sadelain and his colleagues used mouse cells to stimulate the expansion of human tumour-reactive T cells in the laboratory. They found that introducing just 6 genes was enough to create a cell that efficiently stimulates and amplifies human cytotoxic T lymphocytes that break down melanoma cells in vitro. Three genes are used to generate the peptide complex that directly engages the T cell receptor. The other 3 genes enhance T cell activation by engaging other receptors expressed by the responding T cell.

"To our surprise, these artificial antigen-presenting cells worked at least as well as dendritic cells, the most potent naturally occurring antigen-presenting cells, under the experimental conditions used so far," says Dr. Sadelain.

The next step, he adds, is to confirm that artificial antigen-presenting cells can be generally applied to induce tumour-specific T cells in the laboratory. "We will initially focus on antigens found in lymphomas, leukemias and prostate cancer. We also plan to assess the efficacy of these T cells in animal studies. We intend to develop a system that could also permit stimulation of T cells against more than 1 antigen at a time." — Donalee Moulton, Halifax

Comments Send a letter to the editor
Envoyez une lettre à la rédaction

© 2000 Canadian Medical Association or its licensors